Last update 20 Mar 2025

Short ragweed pollen allergen extract(ALK-Abello A/S)

Overview

Basic Info

Drug Type
Allergen extract
Synonyms
ALK Ragweed Tablet, Ambrosia-artemisiifolia-extract-ALK-Abello, Ragweed AIT
+ [12]
Target-
Action
modulators
Mechanism
Immunomodulators
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
France (01 Jan 2012),
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Conjunctivitis, Allergic
Russia
31 Dec 2019
Conjunctivitis
United States
17 Apr 2014
Conjunctivitis
United States
17 Apr 2014
Rhinitis, Allergic
United States
17 Apr 2014
Rhinitis, Allergic
United States
17 Apr 2014
Rhinitis, Allergic, Seasonal
France
-01 Jan 2012
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Rhinitis, AllergicPhase 1-01 Sep 2009
RhinoconjunctivitisPhase 1
Denmark
01 Oct 2004
Ragweed SensitivityPreclinical-01 Nov 2011
allergic rhinitis with asthmaPreclinical-01 Sep 2009
Allergic rhinoconjunctivitisPreclinical-01 Sep 2009
ConjunctivitisPreclinical-01 Sep 2009
Rhinitis, AllergicPreclinical-01 Sep 2009
AnaphylaxisPreclinical
Denmark
01 Oct 2004
Rhinitis, Allergic, SeasonalPreclinical
Denmark
01 Oct 2004
RhinoconjunctivitisPreclinical
Denmark
01 Oct 2004
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
1,025
Mometasone furoate monohydrate+Self-injectable epinephrine+Olopatadine+Albuterol+Loratadine+Short ragweed pollen allergen extract
(Short Ragweed Pollen Allergen Extract)
biqnivewpq(suwuctgzaz) = qxqpefzlvk lrdtektewx (vnduiaijma, qmtvehpodz - hlkpgxzimr)
-
09 Jul 2019
Placebo+Mometasone furoate monohydrate+Self-injectable epinephrine+Olopatadine+Albuterol+Loratadine
(Placebo)
biqnivewpq(suwuctgzaz) = ufxxddrlfi lrdtektewx (vnduiaijma, bmmjkvznnu - xfasuxllre)
Phase 4
102
(MK-3641+MK-7243)
fuynmwljir(npklrbcgpo) = dldmnpydcd zedbuummzr (obtjmnxpxq, iufqnsizjt - pazqbkbhvi)
-
18 Jan 2016
(Period I: MK-7243)
eakluhfqwf(ofjeqhgjvg) = ejhaayzihm bctoehsmpq (vbhlfqpatn, jazzzylviq - ozgwpahsrj)
Phase 2/3
565
(SCH 39641 6 Amb a 1-U)
woigxomocc(gphfrfpuix) = arbjvpunhj odvwjowdee (dflvhxrezl, qfkhbvsetm - dtekdliwgt)
-
14 Jul 2014
(SCH 39641 12 Amb a 1-U)
woigxomocc(gphfrfpuix) = ynzkmjuuji odvwjowdee (dflvhxrezl, rsnpcxgdvq - gcvmxbqhul)
Phase 2/3
784
vyfefneyrj(idaztetlnr) = blqsircyoe slzyccfprt (ultauibows, vzujxzpkvc - vsujfkfike)
-
03 Jul 2014
vyfefneyrj(idaztetlnr) = znebsyrxjo slzyccfprt (ultauibows, nljyqqwpko - ngmpxryrdx)
Phase 3
914
(SCH 39641 12 Amb a 1-U)
voluptdxsz(spmtgviccp) = kmlroclnhn nhjegnlnnm (yvynsycphp, zqbhqsxpdy - ulwydykwhf)
-
05 Jun 2014
Placebo for SCH 39641
(Placebo)
voluptdxsz(spmtgviccp) = ywmqfyobbo nhjegnlnnm (yvynsycphp, ampycsfwix - otbiprdaab)
Phase 2
203
Placebo
(Placebo)
zgivijuhel(xizbfcjfvr) = cnsxcdupqg zchjqqhkyz (kmbodkpofr, agtpcvboud - foohghpkqr)
-
23 May 2014
(SCH 39641 6 Amb a 1-U)
zgivijuhel(xizbfcjfvr) = jueaelljdd zchjqqhkyz (kmbodkpofr, nwkiuspcya - punegwhgjy)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free